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In this article, we present data on endothelial Nitric Oxide Syn-
thase (eNOS) gene T786C and G894T polymorphisms in Greek
steady-state Sickle Cell Disease patients in comparison to healthy
controls. Moreover, eNOS mRNA levels were determined in per-
ipheral blood samples from 18 patients and 9 controls. This article
complements our recently published article named “Prognostic
value of eNOS T786C and G894T polymorphisms in Sickle Cell
Disease” (I. Armenis, V. Kalotychou, R. Tzanetea, Z. Kontogeorgiou,
D. Anastasopoulou, M. Mantzourani, M. Samarkos, K. Pantos, K.
Konstantopoulos, I. Rombos, 2016) [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.niox.2016.11.002
menis).
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Dubject area Genetics, Hematology
ore speciﬁc subject
areaeNOS T786C, G894T polymorphisms, eNOS mRNA levelsype of data Table, image, ﬁgure
ow data was
acquiredVenous blood from 79 patients and 48 controlsata format Analyzed
xperimental factors Venous blood was collected from steady-state Sickle Cell Disease patients and
healthy controls
xperimental
featuresDNA extraction, RNA extraction, PCR, RFLPs, Sanger sequencing, qRT-PCRata source location Greek non-consanguineous Sickle Cell Disease patients
ata accessibility Data is with this articleD
Value of the data
 Genotype and allele distribution of eNOS T786C and G894T polymorphisms were studied for the
ﬁrst time in Greek Sickle Cell Disease patients.
 This is the ﬁrst study to ﬁnd higher prevalence of the C allele in comparison to T for the -786
position in Sickle Cell Disease.
 Peripheral blood eNOS mRNA levels, as an index of eNOS expression, were studied and analyzed
according to the presence or absence of Sickle Cell Disease and eNOS promoter T786C
polymorphism.1. Data
Genotype and allele distribution for polymorphisms T786C and G894T in patients and controls are
presented in Tables 1 and 2 respectively. No statistically signiﬁcant differences were obtained [1].
eNOSmRNA levels normalized to GAPDH are presented in Fig. 1 (Sickle Cell Disease patients relative to
controls) and Fig. 2 (patients of eNOS 786TC and CC genotypes relative to patients of TT genotype).2. Experimental design, materials and methods
2.1. Study population
Seventy nine consecutive Greek SCD patients (mean age: 48.8711.5 years, 25–76 years, 25 male,
54 female) and forty eight Greek healthy controls were enrolled. The study was approved by the
Hospital Ethics Committee in accordance to Helsinki Declaration. All patients were at steady state at
the time of sample collection (no painful crises or other acute complications during the last three
months) and they had not been transfused for the last three months.
2.2. DNA extraction and eNOS genotyping
Genomic DNA was isolated from peripheral blood using the PureLink Genomic DNA extraction kit
(Invitrogen). Nucleotide substitutions T786C and G894T were detected using Sanger sequencing and
PCR-RFLPs techniques respectively. The PCR primers used were as follows:
for T786C: 50ATGCTCCCACCAGGGCATCA30 (forward),
50GTCCTTGAGTCTGACATTAGGG30 (reverse) covering a fragment of 237 bp.
Table 2
Genotype and allele frequencies for eNOS G894T polymorphism in Sickle Cell Disease patients and controls.
Frequencies P
Sickle Cell Disease patients
(n¼79)
Controls
(n¼48)
Genotypes
GG vs GTþTT 50.6% vs 49.4% 39.6% vs 60.4% 0.226
TT vs GGþGT 19.0% vs 81.0% 12.5% vs 87.5% 0.340
Alleles
G vs T 65.8% vs 34.2% 63.6% vs 36.4% 0.712
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Fig. 1. eNOS mRNA levels in Sickle Cell Disease patients (n¼18) and healthy controls (n¼9), relative to GAPDH mRNA. Sickle
Cell Disease patients: 1.0670.84, Controls: 1.3070.92, P¼0.105.
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Fig. 2. eNOS mRNA levels relative to GAPDH in Sickle Cell Disease patients, according to their eNOS T786C genotype: TT:
1.2270.89, TC: 2.4571.88, CC: 2.1071.87, P¼0.454.
Table 1
Genotype and allele frequencies for eNOS T786C polymorphism in Sickle Cell Disease patients and controls.
Frequencies P
Sickle Cell Disease patients
(n¼79)
Controls
(n¼48)
Genotypes
TT vs TCþCC 21.5% vs 78.5% 10.4% vs 89.6% 0.173
CC vs TTþTC 46.8% vs 53.2% 47.9% vs 52.1% 0.906
Alleles
T vs C 37.3% vs 62.7% 31.3% vs 68.7 0.324
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Image 1. Sanger sequencing results from 3 samples of 786CC, TT and TC genotype respectively.
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GT TT GG 100bp ladder
206bp
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Image 2. Agarose gel electrophoresis. Three samples were digested with MboI restriction enzyme, after PCR ampliﬁcation for
eNOS G894T polymorphism.
I. Armenis et al. / Data in Brief 10 (2017) 192–197196and for G894T: 50CATGAGGCTCAGCCCCAGAAC30 (forward), 50AGTCAATCCCTTTGGTGCTCAC30 (reverse)
covering a fragment of 206 bp.
PCR conditions for T786C were: 92 °C for 15 s, 62 °C for 30 s, and 72 °C for 30 s repeated for 34
cycles. For G894T, we applied the previous conditions decreasing the annealing temperature to 58 °C.
Presence of 786C polymorphism was determined by Sanger sequencing of the PCR product using the
above mentioned PCR primers, as shown in Image 1. The 894T polymorphism was detected by PCR-
RFLPs, digesting with the appropriate restriction enzyme, MboI, revealing two fragments of 119 base
pairs and 87 base pairs, as shown in Image 2.
2.3. RNA extraction and quantitative real-time PCR
Eighteen SCD patients (5 male and 13 female) underwent eNOS expression study. Total RNA was
isolated from peripheral blood of the above patients and 9 controls (4 male and 5 female), none of
them smoking or receiving drugs apart from folate supplementation and acetylsalicylic acid. The
RNeasy Mini Kit and Qiashredder homogenizer (Qiagen) after selective lysis of erythrocytes were
applied. One microgram of total RNA was reverse-transcribed using the iScript™ cDNA SynthesisKit
(Bio-Rad). Fifty nanograms of cDNA were used for eNOS quantiﬁcation on a CFX-96 real-time PCR
(Bio-Rad CFX96TouchTM) using hydrolysis probes for eNOS gene and for GAPDH as a reference gene
(Applied Biosystems). Ampliﬁcation was performed with the appropriate cycling parameters, 95 °C
for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Measurements were performed
in duplicate using the iTaq™ Universal Probes supermix (Biorad). Relative gene expression data were
analyzed using the Livak 2ΔΔCt method.
2.4. Statistical analysis
Frequencies of genotypes and clinical characteristics were compared using Pearson's chi-square
test and Fischer-exact test, where applicable. The general, dominant and recessive genetic models, as
well as allele frequencies were used to compare patients and normal controls. Quantitative data were
expressed as mean7S.D. and were compared with Analysis of Variance (ANOVA) or Mann–Whitney
U test, whether applicable. Levene's F test was applied to estimate equality of variances and Kol-
mogorov–Smirnof test to assess deviation from normal distribution. A P-value lower than 0.05 was
considered as statistically signiﬁcant.
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